PMC:7161517 / 470-847 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":207,"end":220},"obj":"Disease"},{"id":"T7","span":{"begin":279,"end":301},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"}],"text":"cause angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/An"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T3","span":{"begin":137,"end":140},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"cause angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/An"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":6,"end":20},"obj":"Chemical"},{"id":"T7","span":{"begin":6,"end":17},"obj":"Chemical"},{"id":"T8","span":{"begin":18,"end":20},"obj":"Chemical"},{"id":"T9","span":{"begin":40,"end":54},"obj":"Chemical"},{"id":"T10","span":{"begin":44,"end":54},"obj":"Chemical"},{"id":"T11","span":{"begin":60,"end":77},"obj":"Chemical"},{"id":"T12","span":{"begin":87,"end":98},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_48432"},{"id":"A6","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_58506"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_25354"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"cause angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/An"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":279,"end":301},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"cause angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/An"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T15","span":{"begin":6,"end":20},"obj":"DG_37;PR:000001118"},{"id":"T16","span":{"begin":21,"end":29},"obj":"PR:000001118"},{"id":"T17","span":{"begin":44,"end":54},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T18","span":{"begin":60,"end":77},"obj":"CHEBI:25354;CHEBI:25354"},{"id":"T19","span":{"begin":78,"end":98},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T20","span":{"begin":108,"end":112},"obj":"PR:000003622;G_3;PG_10"},{"id":"T21","span":{"begin":122,"end":132},"obj":"GO:0010467"},{"id":"T22","span":{"begin":185,"end":191},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T23","span":{"begin":207,"end":212},"obj":"NCBITaxon:10239"},{"id":"T24","span":{"begin":279,"end":293},"obj":"UBERON:0004535"},{"id":"T25","span":{"begin":370,"end":374},"obj":"G_3;PG_10;PR:000003622"},{"id":"T39187","span":{"begin":6,"end":20},"obj":"DG_37;PR:000001118"},{"id":"T33501","span":{"begin":21,"end":29},"obj":"PR:000001118"},{"id":"T28542","span":{"begin":44,"end":54},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T14634","span":{"begin":60,"end":77},"obj":"CHEBI:25354;CHEBI:25354"},{"id":"T38268","span":{"begin":78,"end":98},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T7996","span":{"begin":108,"end":112},"obj":"PR:000003622;G_3;PG_10"},{"id":"T85494","span":{"begin":122,"end":132},"obj":"GO:0010467"},{"id":"T23807","span":{"begin":185,"end":191},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T85043","span":{"begin":207,"end":212},"obj":"NCBITaxon:10239"},{"id":"T68089","span":{"begin":279,"end":293},"obj":"UBERON:0004535"},{"id":"T69502","span":{"begin":370,"end":374},"obj":"G_3;PG_10;PR:000003622"}],"text":"cause angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/An"}

{"project":"LitCovid-PubTator","denotations":[{"id":"26","span":{"begin":40,"end":43},"obj":"Gene"},{"id":"27","span":{"begin":60,"end":86},"obj":"Gene"},{"id":"28","span":{"begin":108,"end":112},"obj":"Gene"},{"id":"29","span":{"begin":370,"end":374},"obj":"Gene"},{"id":"34","span":{"begin":265,"end":273},"obj":"Species"},{"id":"37","span":{"begin":207,"end":220},"obj":"Disease"},{"id":"38","span":{"begin":279,"end":301},"obj":"Disease"}],"attributes":[{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Gene:1636"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Gene:4306"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Gene:59272"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Gene:59272"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Tax:9606"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D001102"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"cause angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/An"}